Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans.
Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected …

that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …

There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the
ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. …

Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …

The SARS-CoV-2 B. 1.617. 2 Delta variant of concern (VOC) continues to drive a sharp increase
in COVID-19 cases in the UK, with a current doubling time of 3· 5–16 days, 1 consistent …

We sought to compare neutralising antibody responses between seronaive haemodialysis
patients and the healthy individuals we have already reported on as part of the Legacy study. …

Recently emerged variants of SARS-CoV-2 contain in their surface spike glycoproteins
multiple substitutions associated with increased transmission and resistance to neutralising …

Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies
(MAbs) have been analysed in three COVID-19 patients with different clinical severities. …

Background: The degree of heterotypic immunity induced by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging …

The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health challenge. While …